Stock Update (NYSE:JNJ): Johnson & Johnson to Participate in the Goldman Sachs 37th Annual Global Healthcare Conference

[PR Newswire] – NEW BRUNSWICK, N.J., May 25, 2016 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8, at the Terranea in Rancho … Read more on this. Johnson & Johnson (JNJ) , currently valued at $312.01B, started the session at $113.18. During today’s session, JNJ traded between $112.85 to $113.72 with its 52-week range being $81.79 to $115.00. JNJ shares are currently priced at 17.05x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 5.55x earnings multiple. The company pays shareholders $3.20 per share in dividend income per year, for a current yield of 2.85%. In a review of the consensus earnings estimate this quarter, 19 sell-side analysts are looking at $1.69 per share, which would be $0.02 worse than the year-ago quarter and a $0.03 sequential increase. What we find to be interesting is that the full-year EPS estimate of $6.61 is a $0.41 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $17.98 Billion. If realized, that would be a 1.07% increase over the year-ago quarter. In terms of ratings, Standpoint Research Initiated JNJ at Sell (May 20, 2016). Previously, Goldman upgraded JNJ from Sell to Neutral. With the above information in mind, readers should note that the average price target is $117.44, which is 3.76% above where the stock opened this morning. See more in (NYSE:JNJ) Similar Articles: Company Update (NYSE:JNJ): Johnson & Johnson Aligns With HP To Create Personalized Healthcare Solutions Stock Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to Webcast Annual Meeting of Shareholders Stock Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to Participate in Barclays Global Healthcare Conference